Founded in 2014, Guangzhou Junmu Biotechnology Co., Ltd. is a high-tech enterprise integrating pharmaceutical research and development, biotechnology services (raw and auxiliary material production) and marketing. The company strictly follows the ISO9001 and CNAS management system for product quality management, and passed the on-site inspection of the China Institute for Food and Drug Control in 2087 and officially became a supplier of reference materials and raw materials.
*The following content is generated by AI and is for reference only.
Overview
This compound is a specialized heterocyclic intermediate featuring a piperazine core linked to benzothienodiazepine moieties. Molecular Formula: C34H38N8S2. CAS No.: Unverified in public databases; likely a custom synthesis target for oncology research. Core process involves multi-step condensation of substituted benzothienodiazepines with piperazine derivatives under strict anhydrous conditions.
Application
- Pharmaceutical R&D: Precursor for novel kinase inhibitors targeting specific cancer pathways.
- Medicinal Chemistry: Scaffold optimization in structure-activity relationship (SAR) studies.
- Biochemical Assays: Component in high-throughput screening libraries for receptor binding.
Precautions
- Storage: Maintain at -20°C under inert atmosphere to prevent hydrolysis.
- PPE: Handle in fume hood; wear nitrile gloves and safety goggles due to potential mutagenicity.
- Regulatory: Not approved for clinical use; strictly for laboratory research only.